Table of Contents
ISRN Pharmaceutics
Volume 2012, Article ID 932542, 11 pages
http://dx.doi.org/10.5402/2012/932542
Research Article

The Role of the Immune System in Nevirapine-Induced Subclinical Liver Injury of a Rat Model

Department of Pharmacology, University of the Free State, P.O. Box 339 (G6), Bloemfontein 9300, South Africa

Received 18 April 2012; Accepted 26 June 2012

Academic Editors: A. Ghosal and C. Saturnino

Copyright © 2012 Zanelle Bekker et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. McKoy, C. L. Bennett, M. H. Scheetz et al., “Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project,” Drug Safety, vol. 32, no. 2, pp. 147–158, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. S. M. Patel, S. Johnson, S. M. Belknap, J. Chan, B. E. Sha, and C. Bennett, “Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals,” Journal of Acquired Immune Deficiency Syndromes, vol. 35, no. 2, pp. 120–125, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Martínez, J. L. Blanco, J. A. Arnaiz et al., “Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy,” AIDS, vol. 15, no. 10, pp. 1261–1268, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. D. T. Dieterich, P. A. Robinson, J. Love, and J. O. Stern, “Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors,” Clinical Infectious Diseases, vol. 38, supplement 2, pp. S80–S89, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. J. O. Stern, P. A. Robinson, J. Love, S. Lanes, M. S. Imperiale, and D. L. Mayers, “A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients,” Journal of Acquired Immune Deficiency Syndromes, vol. 34, supplement 1, pp. S21–S33, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Popovic, J. L. Caswell, B. Mannargudi, J. M. Shenton, and J. P. Uetrecht, “Study of the sequence of events involved in nevirapine-induced skin rash in Brown Norway rats,” Chemical Research in Toxicology, vol. 19, no. 9, pp. 1205–1214, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. J. M. Shenton, M. Teranishi, M. S. Abu-Asab, J. A. Yager, and J. P. Uetrecht, “Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat,” Chemical Research in Toxicology, vol. 16, no. 9, pp. 1078–1089, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. J. M. Shenton, M. Popovic, J. Chen, M. J. Masson, and J. P. Uetrecht, “Evidence of an immune-mediated mechanism for an idiosyncratic nevirapine-induced reaction in the female brown Norway rat,” Chemical Research in Toxicology, vol. 18, no. 12, pp. 1799–1813, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. X. Deng, R. F. Stachlewitz, M. J. Liguori et al., “Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation,” Journal of Pharmacology and Experimental Therapeutics, vol. 319, no. 3, pp. 1191–1199, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Jaeschke, “Role of inflammation in the mechanism of acetaminophen-induced hepatotoxicity,” Expert Opinion on Drug Metabolism & Toxicology, vol. 1, no. 3, pp. 389–397, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. Z. X. Liu, S. Govindarajan, and N. Kaplowitz, “Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity,” Gastroenterology, vol. 127, no. 6, pp. 1760–1774, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. Z. X. Liu and N. Kaplowitz, “Role of innate immunity in acetaminophen-induced hepatotoxicity,” Expert Opinion on Drug Metabolism and Toxicology, vol. 2, no. 4, pp. 493–503, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. Z. X. Liu and N. Kaplowitz, “Immune mechanisms in drug-induced hepatotoxicity,” in Liver Immunology: Principles and Practice, M. E. Gershwin, J. M. Vierling, and M. P. Manns, Eds., pp. 363–374, Humana Press, Totowa, NJ, USA, 2007. View at Google Scholar
  14. J. P. Luyendyk, J. F. Maddox, G. N. Cosma, P. E. Ganey, G. L. Cockerell, and R. A. Roth, “Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 307, no. 1, pp. 9–16, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. P. J. Shaw, M. J. Hopfensperger, P. E. Ganey, and R. A. Roth, “Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha,” Toxicological Sciences, vol. 100, no. 1, pp. 259–266, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. M. P. Holt and C. Ju, “Mechanisms of drug-induced liver injury,” AAPS Journal, vol. 8, no. 1, pp. E48–E54, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Priimägi, V. Tefanova, T. Tallo, and E. Schmidt, “The role of serum Th1 and Th2 cytokines in patients with chronic hepatitis B and hepatitis C virus infection,” Acta Medica Lituanica, vol. 12, no. 3, pp. 28–31, 2005. View at Google Scholar
  18. K. M. Kulmatycki and F. Jamali, “Drug disease interactions: role of inflammatory mediators in disease and variability in drug response,” Journal of Pharmacy and Pharmaceutical Sciences, vol. 8, no. 3, pp. 602–625, 2005. View at Google Scholar · View at Scopus
  19. K. M. Chu, A. M. Boulle, N. Ford, E. Goemaere, V. Asselman, and G. Van Cutsem, “Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care art programme in South Africa,” PLoS ONE, vol. 5, no. 2, Article ID e9183, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Medrano, P. Barreiro, P. Tuma et al., “Risk for immune-mediated liver reactions by nevirapine revisited,” AIDS Reviews, vol. 10, no. 2, pp. 110–115, 2008. View at Google Scholar · View at Scopus
  21. A. Walubo, S. Barr, and A. M. Abraham, “Rat CYP3A and CYP2B1/2 were not associated with nevirapine-induced hepatotoxicity,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 28, no. 7, pp. 423–431, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. B. Wen, Y. Chen, and W. L. Fitch, “Metabolic activation of nevirapine in human liver microsomes: dehydrogenation and inactivation of cytochrome P450 3A4,” Drug Metabolism and Disposition, vol. 37, no. 7, pp. 1557–1562, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Chen, B. M. Mannargudi, L. Xu, and J. Uetrecht, “Demonstration of the metabolic pathway responsible for nevirapine-induced skin rash,” Chemical Research in Toxicology, vol. 21, no. 9, pp. 1862–1870, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. A. M. M. Antunes, A. L. A. Godinho, I. L. Martins, G. C. Justino, F. A. Beland, and M. M. Marques, “Amino acid adduct formation by the nevirapine metabolite, 12-Hydroxynevirapine- a possible factor in nevirapine toxicity,” Chemical Research in Toxicology, vol. 23, no. 5, pp. 888–899, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. L. A. Stanley, D. J. Adams, R. Lindsay, R. R. Meehan, W. Liao, and C. R. Wolf, “Potentiation and suppression of mouse liver cytochrome P-450 isozymes during the acute-phase response induced by bacterial endotoxin,” European Journal of Biochemistry, vol. 174, no. 1, pp. 31–36, 1988. View at Google Scholar · View at Scopus
  26. E. T. Morgan, “Suppression of constitutive cytochrome P-450 gene expression in livers of rats undergoing an acute phase response to endotoxin,” Molecular Pharmacology, vol. 36, no. 5, pp. 699–707, 1989. View at Google Scholar · View at Scopus
  27. H. G. Jeong, “Cytokine-mediated suppression of cytochrome P450 1A1 in Hepa-1c1c7 cells by pokeweed mitogen,” Toxicology Letters, vol. 119, no. 2, pp. 125–132, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. A. E. Aitken and E. T. Morgan, “Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes,” Drug Metabolism and Disposition, vol. 35, no. 9, pp. 1687–1693, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. C. A. Dinarello, “Proinflammatory cytokines,” Chest, vol. 118, no. 2, pp. 503–508, 2000. View at Google Scholar · View at Scopus
  30. R. M. Locksley, N. Killeen, and M. J. Lenardo, “The TNF and TNF receptor superfamilies: integrating mammalian biology,” Cell, vol. 104, no. 4, pp. 487–501, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. S. M. Opal and V. A. DePalo, “Anti-inflammatory cytokines,” Chest, vol. 117, no. 4, pp. 1162–1172, 2000. View at Google Scholar · View at Scopus
  32. A. Srivastava, L. Y. Lian, J. L. Maggs et al., “Quantifying the metabolic activation of nevirapine in patients by integrated applications of NMR and mass spectrometries,” Drug Metabolism and Disposition, vol. 38, no. 1, pp. 122–132, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. X. Chen, T. Tharmanathan, B. Mannargudi, H. Gou, and J. P. Uetrecht, “A study of the specificity of lymphocytes in nevirapine-induced skin rash,” Journal of Pharmacology and Experimental Therapeutics, vol. 331, no. 3, pp. 836–841, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. J. P. Uetrecht, “Role of animal models in the study of drug-induced hypersensitivity reactions,” The AAPS Journal, vol. 7, no. 4, pp. E914–E921, 2005. View at Google Scholar · View at Scopus
  35. R. J. Bosch, R. B. Pollard, A. Landay, E. Aga, L. Fox, and R. Mitsuyasu, “Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328),” AIDS Research and Therapy, vol. 7, article 30, 2010. View at Publisher · View at Google Scholar · View at Scopus